Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2018 Jul 11;17(9):1902–1916. doi: 10.1158/1535-7163.MCT-18-0373

Fig 2. SP-2509 but not GSK-LSD1 significantly reduces the proliferative capacity of Ewing sarcoma cell lines.

Fig 2

(A) SP-2509 hypersensitive (A673, TC252) and sensitive (ES-2) Ewing sarcoma cell lines treated with the indicated concentrations of SP-2509, GSK-LSD1, Doxorubicin or vehicle control (DMSO) for 96hrs. Proliferative capacity and induction of apoptosis (caspase 3/7 activity) was measured in real-time through IncuCyte ZOOM live cell imaging. Data represents mean ± SEM confluency or green object count, from three independent experiments. (B) Statistical analysis of proliferation or caspase 3/7 induction compared to vehicle control cells (ns: not significant). (C) Representative phase contrast and green fluorescence (caspase 3/7) images following 72hrs of treatment with the indicated agents.